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Introduction: Brugada syndrome (BrS) is a cardiac ion channelopathy with a
higher prevalence in Asia compared to the Western populations. The present study
compared the differences in clinical and electrocardiographic (ECG) presentation
between paediatric/young (≤25 years old) and adult (>25 years) BrS patients.
Method: This was a territory-wide retrospective cohort study of consecutive BrS
patients presenting to public hospitals in Hong Kong. The primary outcome was
spontaneous ventricular tachycardia/ventricular fibrillation (VT/VF).
Results: The cohort consists of 550 consecutive patients (median age of initial
presentation = 51 ± 23 years; female = 7.3%; follow-up period = 83 ± 80 months),
divided into adult (n = 505, mean age of initial presentation = 52 ± 19 years; female
= 6.7%; mean follow-up period = 83 ± 80 months) and paediatric/young subgroups
(n= 45, mean age of initial presentation= 21± 5 years, female= 13.3%,mean follow-up
period= 73± 83 months). The mean annual VT/VF incidence rate were 17 and 25 cases
per 1,000 patient-year, respectively. Multivariate analysis showed that initial presentation
of type 1 pattern (HR = 1.80, 95% CI = [1.02, 3.15], p = 0.041), initial asymptomatic
presentation (HR = 0.26, 95% CI = [0.07, 0.94], p = 0.040) and increased P-wave axis
(HR = 0.98, 95% CI = [0.96, 1.00], p = 0.036) were significant predictors of VT/VF for
the adult subgroup. Only initial presentation of VT/VF was predictive (HR = 29.30, 95%
CI = [1.75, 492.00], p = 0.019) in the paediatric/young subgroup.
Conclusion: Clinical and ECG presentation of BrS vary between the paediatric/young
and adult population in BrS. Risk stratification and management strategies for younger
patients should take into consideration and adopt an individualised approach.
Keywords: Brugada syndnrome, paediatric, risk stratification, ventricular arrhythmia, sudden cardiac death
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INTRODUCTION
Cardiac channelopathies are primary electrophysiological
disorders that predispose spontaneous ventricular
tachycardia/fibrillation (VT/VF) and sudden cardiac death
(SCD) in the absence of structural abnormalities (1–3).
Brugada syndrome (BrS), congenital long QT syndrome, and
catecholaminergic ventricular tachycardia are the most common
hereditary cardiac ion channelopathies (4–6). Although SCD
in young people is more commonly caused by hypertrophic
cardiomyopathy in the United States and arrhythmogenic right
ventricular cardiomyopathy in parts of Europe, cardiac ion
channelopathies often underly juvenile cases of SCD without
pre-existing comorbidities, which can cause great distress toward
patients’ families and the general public (7, 8).
Of these conditions, BrS is the most prevalent ion
channelopathy found in Asia (9–12). BrS typically manifests
in the fourth to fifth decades of life, but those presenting in
childhood are deemed to be at high risk of SCD if symptomatic
(13, 14). Due to the small population of paediatric BrS patients,
it can be challenging to identify the specific differences
between the paediatric and adult populations. As a result, the
application of adult-based risk stratification criteria upon the
paediatric population may result in misinterpretation of SCD
risk. The present study aims to demonstrate the difference in
clinical and electrocardiographic (ECG) presentation between
paediatric/young and adult BrS patients.
METHODS
Study Population
This study was approved by The Joint Chinese University of
Hong Kong—New Territories East Cluster Clinical Research
Ethics Committee. The cohort included consecutive patients
diagnosed with BrS between January 1st, 1997 and June 20th,
2020 by public hospitals of Hong Kong. Centralised electronic
health records from the Hospital Authority were reviewed for
patient identification and data extraction. The diagnosis of BrS
was made initially by the case physicians. They were confirmed
by G.T. andN.S.M. through the review of case notes, documented
ECGs, treadmill test results, and genetic reports. Diagnosis of
BrS was made based on the 2017 criteria proposed by the Expert
Consensus Statement, as used in previous studies by our group
(15). These patients fulfilled either criteria of (1) presentation of
type 1 Brugada ECG pattern (BrP), or; (2) presentation of type
2 BrP with positive flecainide challenge test or VT/VF-induced
on the electrophysiological study (EPS). Patients ≤25 years old
were categorised into the paediatric/young subgroup, with the
remainder of patients categorised into the adult subgroup. The
age cut-off was adopted from Gonzalez et al.’s study on the risk
stratification amongst young Brugada patients (14).
Clinical and Electrocardiographic Data
Collection
The baseline clinical data extracted from the electronic health
records include: (1) sex; (2) age of first characteristic ECG
presentation and last follow-up; (3) follow-up duration; (4)
family history of SCD and BrS; (5) syncope manifestation
and its frequency; (6) presentation of sustained VT/VF and
its frequency; (7) ECG details as mentioned below; (8)
performance of EPS, 24-h Holter study, genetic testing, and
the respective results; (9) performance of echocardiogram;
(10) presence of other arrhythmias; (11) implantation of
implantable cardioverter-defibrillator (ICD); (12) occurrence,
cause, and age of death; (13) period between the initial
presentation of characteristic ECG and the first post-diagnosis
VT/VF episode; (14) initial disease manifestation (asymptomatic,
syncope, VT/VF). In the present study, symptoms refer to
syncope and VT/VF, thus asymptomatic indicates freedom
from both presentations. Other arrhythmias include sick sinus
syndrome, atrioventricular block, atrial tachyarrhythmias, and
supraventricular tachyarrhythmias. Positive EPS is defined as the
induction of VT/VF that either sustained a minimum of 30 s or
produced hemodynamic collapse.
In addition to the aforementioned details, the following
clinical data on BrP were extracted: (1) the presence of fever and
type of BrP; (2) any presentation of type 1 BrP during follow-
up; (3) evolution in BrP type during follow-up; (4) performance
and results of the flecainide challenge. The presence of type 1 BrP
and the evolution of BrP types were identified by G.T. and S.L.
through reviewing all documented ECGs from the BrS cohort.
The following automatically measured indices from the
baseline ECG was extracted: (1) heart rate; (2) P wave duration
(PWD) and PR interval; (3) QRS duration; (4) QT and QTc
interval; (5) P, QRS, and T wave axis; (6) amplitude of R and
S wave from leads V5 and V1, respectively; (7) presence of 1st
degree atrioventricular block, defined as PR-interval >200ms;
(8) presence of interventricular delay, defined as QRS-interval
≥110ms. Baseline ECG is the documented ECG with the initial
characteristic ECG presentation. All ECG parameters, except for
the amplitude of R and Swave from leads V5 andV1, respectively,
were averaged across the 12 leads. These indices were selected
as they reflect BrS- associated electrocardiographic changes, such
as electrical axis deviation, and electrocardiographic indices that
are used for risk stratification, such as depolarization parameters
including prolonged QRS, 1st-degree atrioventricular block,
positive R wave in lead V1, and QTc prolongation (16–19).
Statistical Analysis
Given the Shapiro–Wilk’s normality test shows that all
parameters were not normally distributed with P < 0.05,
non-parametric tests were adopted. Subgroup differences of
categorical variables were compared through Fisher’s exact test
and reported as total number (percentage), whilst discrete and
continuous variables were compared by the Mann–Whitney
U-test (median± interquartile range [IQR]). The annual VT/VF
and case incidence rate of each subgroup was calculated by
dividing the number of sustained VT/VF episodes and the
number of patients with VT/VF during follow-up, respectively,
by the sum of the follow-up duration in the subgroup. Cox
regression was used to identify independent predictors of
time to first post-diagnosis sustained VT/VF. The hazard ratio
(HR) and 95% confidence interval (CI) were reported for Cox
regression. Univariate predictors with P < 0.05 were selected
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TABLE 1 | Baseline characteristics of the Brugada syndrome cohort.
Characteristic Overall (n = 550) Adult (n = 505) Paediatric/Young (n = 45) P-value
Demographics and clinical presentation
Female 40 (7.27) 34 (6.73) 6 (13.3) 0.126
Onset age 51 ± 23 52 ± 19 21 ± 5 -
Current age 58 ± 23 60 ± 19 27 ± 9 -
Initial type 1 BrP 341 (62.0) 312 (61.8) 29 (64.4) 0.631
Type 1 BrP 413 (75.1) 381 (75.4) 31 (71.1) 0.716
Evolution of BrP type 188 (34.2) 171 (33.9) 17 (37.8) 0.513
Fever 87 (15.8) 74 (14.7) 13 (28.9) 0.018
Family history of BrS 17 (3.09) 12 (2.38) 5 (11.1) 0.009
Family history of SCD 45 (8.18) 40 (7.92) 5 (11.1) 0.401
Syncope 237 (43.1) 213 (42.2) 24 (53.3) 0.160
Syncope frequency 1.49 ± 16.4 1.54 ± 17.1 0.933 ± 1.19 0.162
VT/VF 86 (15.6) 77 (15.2) 9 (20.0) 0.394
Sustained VT/VF frequency 0.77 ± 4.16 0.80 ± 4.33 0.42 ± 1.01 0.294
Initial asymptomatic 332 (60.4) 312 (61.8) 20 (44.4) 0.026
Initial symptomatic 218 (39.6) 193 (38.2) 25 (55.5) 0.023
Initial syncope 175 (31.8) 154 (30.5) 21 (46.7) 0.030
Initial VT/VF 43 (7.82) 39 (7.72) 4 (8.89) 0.771
Initial diagnostic evaluation
Flecainide challenge 234 (42.5) 209 (41.4) 25 (55.6) 0.083
Positive flecainide challenge 204 (87.2) 185 (88.5) 19 (76.0) 0.114
EPS 112 (20.4) 108 (21.4) 4 (8.89) 0.052
Positive EPS 76 (67.9) 74 (68.5) 2 (50.0) 0.596
Holter study 153 (27.8) 139 (27.5) 14 (31.1) 0.605
Arrhythmia in Holter Study 64 (41.8) 62 (44.6) 2 (14.3) 0.048
Other arrhythmias 81 (14.7) 79 (15.6) 2 (4.44) 0.046
Genetic test 53 (9.64) 45 (8.91) 8 (17.8) 0.064
Positive genetic test 18 (34.0) 13 (28.9) 5 (62.5) 0.104
Echocardiogram 259 (47.1) 236 (46.7) 23 (51.1) 0.641
EEG 61 (11.1) 55 (10.9) 6 (13.3) 0.619
Positive EEG 16 (26.2) 16 (29.1) 0 (0.00) 0.325
Treatment and outcomes
ICD 143 (26.0) 135 (26.7) 8 (17.8) 0.218
Death 39 (7.09) 38 (7.52) 1 (2.22) 0.356
BrS death 6 (1.09) 5 (0.99) 1 (2.22) 1.00
Follow-up duration 83 ± 80 83 ± 80 73 ± 83 0.314
Baseline ECG characteristics
Heart rate 79 ± 26 78 ± 26 86 ± 26.5 0.018
P-wave duration 113 ± 17 113 ± 16 108 ± 15.8 0.160
PR interval 166 ± 31 166 ± 32 158 ± 30 0.022
QRS interval 103 ± 16 104 ± 16 103 ± 17.3 0.883
QT interval 368 ± 48.0 369 ± 48.0 355 ± 48.5 0.004
QTc interval 415 ± 35.0 415 ± 34.5 410 ± 43.8 0.172
P axis 64 ± 24 64 ± 24 60 ± 23 0.508
QRS axis 60 ± 47 58 ± 47 75 ± 39 0.017
T axis 56 ± 28.0 56 ± 27.3 57.5 ± 30.3 0.617
V5 R wave amplitude 1.42 ± 0.76 1.42 ± 0.77 1.25 ± 0.60 0.139
V1S wave amplitude 0.54 ± 0.44 0.54 ± 0.439 0.49 ± 0.98 0.614
1st degree AV block 55 (10.0) 52 (10.3) 3 (6.67) 0.602
Interventricular delay 149 (27.1) 138 (27.3) 11 (24.4) 0.856
For discrete variables, the table presents the number of patients (patient percentage concerning the cohort or subgroup). Bold text indicates P < 0.05.
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for the multivariate analysis to avoid overfitting. To check for
collinearity, variance inflation factor (VIF) is computed for the
parameters in the multivariate analysis. VIF ≥ 5 indicates the
presence of collinearity and the variable in question would be
removed. Separate models with and without the inclusion of
predictors from the baseline ECG were established. Kaplan–
Meier estimator curves were constructed for comparing the
time-to-first VT/VF between paediatric/young and adult
subgroups, and were compared using the log-rank test. All
statistical analysis was performed using R Studio (Version:
1.3.1073). Statistical significance was defined as P < 0.05.
RESULTS
Baseline Characteristics
The baseline characteristics of BrS cohort and subgroups are
presented in Table 1. The BrS cohort consists of 550 consecutive
patients (age of initial presentation = 51 ± 23 years; female
= 7.3%; follow-up period = 83 ± 80 months), divided into
adult (n = 505, mean age of initial presentation = 52 ±
19 years; female = 6.7%; mean follow-up period = 83 ± 80
months) and paediatric/young subgroups (n = 45, mean age
of initial presentation = 21 ± 5 years, female = 13.3%, mean
follow-up period = 73 ± 83 months). Gender (p = 0.126)
and follow-up duration (p = 0.314) did not differ significantly
between the two subgroups. There was no significant intergroup
difference in both the overall (p = 0.716) and initial (p = 0.631)
presentation of type 1 BrP. There was a significantly greater
proportion of paediatric/young patients presenting with fever
at the onset of BrP (p = 0.018), or with a family history of
BrS (p = 0.009). There are 143 patients with ICD implanted,
which consists of eight paediatric/young patients. Amongst the
35 patients who received at least one appropriate shock, three
cases belong to the paediatric/young subgroup, whilst two of
the 24 patients who received inappropriate shocks were in the
paediatric/young subgroup.
Outcomes and Follow-Up
A total of seven paediatric/young and 59 adult patients suffered
from incident VT/VF on follow-up. This is equivalent to an
incidence rate of 0.052 (7 cases per 135 person-days) and 0.0149
(59 cases per 3,965 person-days) for these groups, respectively,
yielding an incidence rate ratio of 3.48 (95% confidence interval:
1.34–7.64). Furthermore, the overall manifestation of syncope
(p = 0.160) and VT/VF (p = 0.394), in addition to their
respective frequencies (syncope = 0.162, sustained VT/VF =
0.294), had no statistically significant difference between the two
groups using the Mann–Whitney U-test. There was a greater
proportion of adults with arrhythmias other VT/VF (p = 0.046),
and arrhythmia detected during Holter monitoring (p = 0.048).
At the initial onset of BrP, a significantly greater proportion
of adult patients were diagnosed asymptomatically (p = 0.026),
whilst paediatric/young patients weremore commonly diagnosed
after the manifestation of syncope (p = 0.030). Amongst the
seven initially asymptomatic paediatric/young patients with fever
and type 1 BrP, no one experienced VT/VF during follow-up.
TABLE 2A | Multivariate Predictors for post-diagnosis VT/VF-free survival in BrS
excluding baseline ECG parameters.
Parameter HR Variance inflation factor 95% CI P-value
Adult (n = 505)
Initial type 1 BrP 1.80 1.06 [1.02, 3.15] 0.041
Initial asymptomatic 0.53 1.28 [0.26, 1.07] 0.076
Initial VT/VF 1.37 1.25 [0.75, 2.52] 0.311
Paediatric/Young (n = 45)
Age 0.94 1.24 [0.83, 1.07] 0.368
Initial VT/VF 19.4 1.24 [1.59, 237] 0.020
Bold text indicates P < 0.05.
TABLE 2B | Multivariate predictors for post-diagnosis VT/VF-free survival in BrS
including baseline ECG parameters.
Parameter HR Variance inflation factor 95% CI P-value
Adult (n = 220)
Initial type 1 BrP 2.74 1.47 [0.98, 7.65] 0.054
Initial asymptomatic 0.26 1.11 [0.07, 0.94] 0.040
Initial VT/VF 1.06 1.28 [0.45, 2.52] 0.897
P Axis 0.98 1.26 [0.96, 0.999] 0.036
Lead V5 R wave amplitude 0.60 1.34 [0.23, 1.58] 0.303
Lead V1S wave amplitude 0.39 1.38 [0.07, 2.18] 0.286
Paediatric/Young (n = 38)
Age 0.95 2.86 [0.78, 1.17] 0.648
Initial VT/VF 13.1 1.79 [0.65, 265.00] 0.093
QTc interval 1.01 3.85 [0.96, 1.05] 0.832
Bold text indicates P < 0.05.
There was no statistically significant intergroup difference in all-
cause mortality (p= 0.356) and BrS-related mortality (p= 1.00).
In terms of baseline ECG indices, paediatric/young patients had
a significantly higher heart rate (p= 0.018), which can contribute
to a shorter QT interval (p= 0.004) in addition to the influence of
age (20). The paediatric/young subgroup also had a significantly
higher QRS axis than the adult subgroup (p= 0.017).
Spontaneous VT/VF Predictors
Different predictors for time-to-first post-diagnosis VT/VF-
free survival were found for the adult and paediatric/young
subgroups on both univariate and multivariate analysis, as
displayed on Tables 2A,B. For the adult subgroup, the following
significant predictors were found on univariate analysis: (1)
initially asymptomatic (HR = 0.53, 95% CI = [0.28, 0.98], p
= 0.042); (2) initial VT/VF presentation (HR = 1.85, 95% CI
= [1.07, 3.19], p = 0.027); (3) P-wave axis (HR = 0.99, 95%
CI = [0.97, 1.00], p = 0.033); (4) R-wave amplitude in lead
V5 (HR = 0.40, 95% CI = [0.17, 0.92], p = 0.030); (5) S-wave
amplitude in lead V1 (HR = 0.20, 95% CI = [0.05, 0.83], p =
0.027). Under multivariate analysis, initial presentation of type
1 BrP is predictive when baseline ECG predictors were excluded
(HR = 1.80, 95% CI = [1.02, 3.15], p = 0.041). When baseline
ECG predictors were included, both the initial asymptomatic
presentation (HR = 0.26, 95% CI = [0.07, 0.94], p = 0.040) and
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FIGURE 1 | Kaplan-Meier survival curve for paediatric/young and adult Brugada syndrome patients.
higher P axis (HR= 0.98, 95% CI= [0.96, 1.00], p= 0.036) were
found to be protective against spontaneous VT/VF.
For the paediatric/young subgroup, age (HR = 0.88, 95% CI
= [0.79, 0.97], p = 0.015), initial VT/VF (HR = 31.9, 95% CI =
[3.31, 308.00], p= 0.003), and baseline QTc interval (HR= 1.04,
95% CI = [1.01, 1.06], p = 0.008) were identified as significant
predictors under univariate analysis. Only the initial presentation
of VT/VF is found to be predictive when baseline ECG predictors
were excluded (HR= 19.40, 95% CI= [1.59, 237.00], p= 0.020).
Additionally, paediatric/young status was found to be predictive
of shorter post-diagnosis VT/VF-free survival (HR = 2.67, 95%
CI = [1.20, 5.95], p = 0.016). Figure 1 illustrates the significant
intergroup difference in VT/VF-free survival with the Kaplan–
Meier survival curve (p = 0.012). The drop in patient number is
solely due to the occurrence of VT/VF during follow-up, with no
patients lost to follow-up.
DISCUSSION
This is the first territory-wide cohort study, to the best of
our knowledge, comparing paediatric/young and adult patients
of BrS patients from Asia. There are several major findings
for the present study: (1) there are significant differences in
clinical and ECG presentation amongst adult and paediatric
patients of BrS; (2) paediatric/young BrS patients have a
higher risk for spontaneous VT/VF; (3) different predictors
for spontaneous VT/VF were found between adult and
paediatric/young BrS patients.
Brugada Syndrome in the Young
Elevated risks of VT/VF occurrence amongst paediatric/young
BrS patients have been reported by existing studies (14, 21–
23). In a multi-centre study from 15 French tertiary centres
including 1,613 patients, age at diagnosis changes the clinical
presentation of BrS (23). The authors found that children
present the highest risk of SCD (23). Whilst ICD therapy has
been reported to be an effective treatment against potentially
lethal arrhythmia in >25% young patients, it is frequently
associated with complications and inappropriate shocks. Thus,
risk stratification for SCD is particularly important amongst
young patients (24). Furthermore, the greater proportion of
fever-induced BrP amongst young patients was reported by
other studies from the Survey on Arrhythmic Events in Brugada
Syndrome (SABRUS) registry (22, 25). In a study of 128
young BrS patients (<=25-year-old), the VT/VF event rate
was 4.5% per year, the presence of spontaneous type 1 BrP,
atrial arrhythmias and conduction abnormalities identified as
significant predictors for ventricular arrhythmic events (14).
In another study, the significant predictors were sinus node
dysfunction, atrial arrhythmias, intraventricular conduction
delay, and large S-wave in the paediatric subgroup, whereas
only the presence of SCN5A mutations was predictive for the
adolescent subgroup (22). Conte et al. (26) reported that children
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experience more frequent episodes of sinus node dysfunction
comparing to older subjects, with a comparable incidence of
atrial tachyarrhythmia. The change in predictiveness of mutation
may be due to a later presence of hormonal and autonomic
triggers in life for the ECG phenotype to appear (27). In
our study, the incidence rate for VT/VF is 17 and 25 cases
per 1,000 patient-years for the adult and paediatric/young
subgroups, respectively.
Initial presentation with VT/VF is a significant predictor
of incident VT/VF, however spontaneous type 1 BrP was not
a predictive factor in the paediatric population. This may be
attributed to a greater proportion of females in the relatively small
paediatric population, because spontaneous type 1 BrP did not
predict spontaneous VT/VF amongst females (28). Previously, it
was found that female BrS patients had a lower arrhythmic risk
(29). This may be due to the role of testosterone in BrS, where
hypertestosteronemia was reported to be positively associated
with the Brugada phenotype (30).
In terms of ECG features, conduction abnormalities were
shown to be predictive of spontaneous VT/VF on follow-up in
paediatric BrS patients (14, 22). In contrast to these findings,
our study identified repolarization (prolonged QTc interval) but
not conduction abnormalities (PR interval, QRS interval, 1st-
degree atrioventricular block) as significant predictors of VT/VF
for the paediatric/young subgroup. This would suggest altered
repolarization playing an important role in mediating ventricular
arrhythmogenesis in this subgroup (31–34). It is hypothesised
that QTc prolongation reflects the increased dispersion in
transmural ventricular repolarization, thus increase the risk
of VT/VF (35–42). Moreover, we found that paediatric/young
patients had a higher QRS axis, in keeping with previous
demonstrations of right axis deviation in younger patients but
this variable was not a predictor of arrhythmic events. However,
there is a lack of significant predictors for spontaneous VT/VF
after the inclusion of baseline ECG predictors, likely due to the
small sample size (n= 38) with a small number of events (n= 7),
hence there is insufficient statistical power for the identification
of significant predictors.
Brugada Syndrome in Adults
Several factors contribute to the differences in clinical and
ECG presentation between paediatric/young and adult BrS
patients. Testosterone has been found to play a significant
role in the male predominant adult BrS population (30). Since
testosterone is found to increase the risk of atrial arrhythmias,
particularly amongst men, this explains the increased incidence
of atrial arrhythmias within the male subgroup, possibly through
increased adrenergic activity (43–45). Furthermore, ST-elevation
and the resulting BrP may only become apparent later in
life, despite a lifelong elevated SCD risk, which may explain
the intergroup differences in ECG indices (46). The inherent
difference in paediatric and adult ECG also contributes to the
ECG subgroup differences, such as the lengthening of PR-interval
as age increases (47).
Furthermore, our study found that higher R-wave and S-wave
amplitudes were significant predictors of lower VT/VF in the
adult subgroup. Indeed, a lower “minimum late R’ and S-wave
duration,” reflecting a reduced voltage, was associated with a
higher incidence of VT/VF (48). Moreover, a higher P-wave axis
was associated with a lower likelihood of VT/VF in the adult
subgroup. Abnormal P-wave axis outside the normal range of
0–75 degrees is known to be associated with atrial fibrillation
and myocardial ischemia (49, 50). Whilst these changes increase
the risk of cardiovascular mortality in the general population, in
Brugada patients it may reflect a longer survival that allows the
development of these degenerative changes.
Strengths and Limitations
The major strengths of the present study include: (1) this is the
first study that compared the characteristics of paediatric/young
and adult patients in BrS; (2) predictors of post-diagnosis
VT/VF-free survival were derived for adult and paediatric/young
patients; (3) holistic differences in clinical and ECG aspects of
adult and paediatric/young patients were evaluated; (4) the study
cohort was followed-up for a substantial length of time.
Several limitations should be noted for the present study.
First, the retrospective nature of the study is inherently subjected
to selection and information bias. However, consultations were
performed at least annually for most patients, hence the patients
were closely followed up. Also, it should be noted that the
documented syncope may not be of cardiogenic origin, hence
it may be unrelated to BrS. Moreover, the heterogeneity of
age within the paediatrics population may limit the statistical
power in the identification of VT/VF predictors. Therefore,
multinational registries on the paediatric population are needed
to expand the cohort size and homogenise the classes of
age in paediatric studies. Furthermore, changes in guidelines
for investigations and diagnostic tests throughout follow-up
introduced inevitable inconsistency in indications for different
tests. Due to the limited availability of public genetic service,
not all BrS patients included in this study underwent genetic
screening, and hence genotype-phenotype correlations could not
be established with greater degrees of certainty.
CONCLUSION
Clinical and ECG presentation of BrS vary between the
paediatric/young and adult population in BrS. Risk stratification
and management strategies for younger patients should take into
consideration and adopt an individualised approach.
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